Chk2 meets Plk3 in damage control.
Herzog
Chris R
CR
The Institute for Cancer Prevention, 1 Dana Road, Valhalla, New York 10595, USA. cherzog@IFCP.US
D000818:Animals; D002453:Cell Cycle / Q000502:physiology*; D018797:Cell Cycle Proteins / Q000378:metabolism*; D002471:Cell Transformation, Neoplastic / Q000235:genetics / Q000378:metabolism*; D064447:Checkpoint Kinase 2; D004249:DNA Damage / Q000502:physiology*; D005057:Eukaryotic Cells / Q000201:enzymology*; D006801:Humans; D009369:Neoplasms / Q000201:enzymology* / Q000235:genetics; D011494:Protein Kinases / Q000378:metabolism*; D017346:Protein Serine-Threonine Kinases / Q000378:metabolism*; D016159:Tumor Suppressor Protein p53 / Q000378:metabolism; D025521:Tumor Suppressor Proteins / Q000378:metabolism; D000097868:Polo-like Kinases
D018797:Cell Cycle Proteins; D064447:Checkpoint Kinase 2; D011494:Protein Kinases; D017346:Protein Serine-Threonine Kinases; D016159:Tumor Suppressor Protein p53; D025521:Tumor Suppressor Proteins; C486256:PLK3 protein, human; D000097868:Polo-like Kinases; C578634:CHEK2 protein, human